English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Significance Cerebral malaria (CM) is a neurological complication of malaria infection that, despite antimalarial drug treatment, results in fatality or neurodisability in approximately 25% of cases. Thus, there is an urgent clinical need to develop therapies that can improve the efficacy of antimalarial drugs to prevent or reverse cerebral pathology. Here, we show in an experimental mouse model of CM (ECM) that IL33 administration can improve survival and reduce pathology in the brain over antimalarial drugs alone. Mechanistically, we demonstrate that IL33 enhances recovery from ECM by inhibiting NLRP3 inflammasome-induced inflammatory responses within the brain. These results suggest that IL33 and NLRP3 inflammasome inhibitors may be effective adjunctive therapies for CM.

Targeting the IL33–NLRP3 axis improves therapy for experimental cerebral malaria